any of these stockholders than the stockholders indicate an interest in purchasing or could determine not to sell any shares to these stockholders.Joint Book-Running ManagersJefferiesCowen and CompanyCo-Lead ManagerCo-ManagerCanaccord GenuityCantor Fitzgerald & Co.Prospectus dated                      , 2014Table of ContentsTABLE OF CONTENTSProspectus Summary1Risk Factors13Special Note Regarding Forward-Looking Statements35Use of Proceeds36Dividend Policy36Capitalization37Dilution40Selected Financial Data43Management's Discussion and Analysis of Financial Condition and Results of Operations45Business70Management114Summary Compensation Table121Certain Relationships and Related Transactions136Security Ownership of Certain Beneficial Owners and Management140Description of Capital Stock145Shares Eligible for Future Sale150Underwriting153Notice to Investors157Where You Can Find Additional Information161Legal Matters161Experts161Index to Financial StatementsF-1Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus.
Low-dose RAD1901 has shown efficacy for the treatment of vasomotor symptoms such as hot flashes in a successful Phase 2 proof of concept study.1Table of ContentsOUR PRODUCT CANDIDATESThe following table identifies the product candidates in our current product portfolio, their proposed indication and stage of development:AbaloparatideAbaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein, or PTHrP, that we are developing as a bone anabolic
the following advantages over other current standard of care treatments for BCBM:•ability to penetrate the blood-brain barrier;•oral administration; and•treatment of hormone-resistant breast cancers.We intend to advance the development of RAD1901 with the initiation of two Phase 1 clinical trials — a maximum tolerated dose study that has commenced patient screening, and
loss per share, see note 2 to our audited financial statements and note 2 to our unaudited financial statements, each of which are included elsewhere in this prospectus.11Table of ContentsAS OF MARCH 31, 2014BALANCE SHEET DATA:ACTUALPRO FORMA(1)PRO FORMAAS ADJUSTED(1)(2)(unaudited, in thousands)Cash, cash equivalents and marketable securities$29,558$29,558$76,323Working capital2,2752,27549,040Total assets31,90631,90678,671Total convertible preferred stock294,032——Total stockholders' (deficit) equity(296,247)(2,215)44,550(1)Gives
additional capital, we may be unable to complete our planned preclinical and clinical trials and obtain approval of any product candidates from the FDA and other regulatory authorities.
including the scope and progress made in our research and development activities and our clinical studies.We are not currently profitable and may never become profitable.We have a history of net losses and expect to incur substantial losses and have negative operating cash flow for the foreseeable future, and may never
including:•continuing to undertake preclinical development and clinical trials;•participating in regulatory approval processes;•formulating and manufacturing products; and•conducting sales and marketing activities.Our
financial results and cause our stock price to fall.Risks related to the discovery, development and commercialization of our product candidatesWe are heavily dependent on the success of Abaloparatide-SC, which is under clinical development.
or be successfully commercialized even if we receive regulatory approval.Abaloparatide-SC is our only product candidate in late stage clinical development, and our business currently depends heavily on its successful
delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the company to decline and limit our ability to obtain
which could harm our business and the value of our common stock.The Phase 3 clinical trial and subsequent extension studies of Abaloparatide-SC are being managed by Nordic at certain clinical sites operated
representing the difference between our pro forma net tangible book value per share as of March 31, 2014 after giving effect to this offering and the assumed public offering price.We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.As a public company listed on the NASDAQ Global Market, we will incur significant legal, accounting and other expenses that we did not incur as a
and the related notes and the information set forth under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations."35Table of ContentsUSE OF PROCEEDSWe estimate that our net proceeds from this offering will be approximately $46.8 million, assuming an initial public offering price of $8.00
financial statements and related notes, all included elsewhere in this prospectus.AS OF MARCH 31, 2014ACTUALPRO FORMAPRO FORMAAS ADJUSTED(1)(In thousands, except share andper share data)Cash, cash equivalents and marketable securities$29,558$29,558$76,323Convertible preferred stock, par value $.0001 per share: 4,571,443 shares authorized, 3,907,741 shares outstanding, actual; no shares authorized, issued or
per share to new investors purchasing common stock in this offering.The pro forma and pro forma as adjusted net tangible book value does not give effect to additional borrowings of approximately $21.0 million under our new credit facility entered into on
The following table illustrates this dilution on a per share basis.Assumed initial public offering price per share$8.00Historical net tangible book value (deficit) per share as of March 31, 2014$(768.15)Pro forma increase per share attributable to conversion of convertible preferred stock and issuance of shares of common stock in satisfaction of
public offering price in this offering, as described in more detail in the section of this prospectus entitled "Capitalization — Series B-2 Convertible Preferred Stock";•1,330,995 shares of our common stock issuable upon the exercise of
We have recently completed a successful Phase 2 proof of concept study of Abaloparatide-TD.Our current clinical product portfolio also includes a novel oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD.
We have recently completed a successful Phase 2 proof of concept study of Abaloparatide-TD.Our current clinical product portfolio also includes a novel oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD.